Research Papers:

MicroRNA-610 inhibits tumor growth of melanoma by targeting LRP6

Guangjing Zhang, Dongfang Ai, Xiufang Yang, Shanshan Ji, Zhengxiang Wang and Shijun Feng _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:97361-97370. https://doi.org/10.18632/oncotarget.22125

Metrics: PDF 1693 views  |   HTML 1847 views  |   ?  


Guangjing Zhang1, Dongfang Ai1, Xiufang Yang1, Shanshan Ji1, Zhengxiang Wang1 and Shijun Feng1

1Department of Dermatology, Cangzhou Central Hospital, Cangzhou, Hebei 061001, P.R. China

Correspondence to:

Shijun Feng, email: [email protected]

Keywords: microRNA-610; melanoma; LRP6; proliferation; apoptosis

Received: July 29, 2017    Accepted: August 29, 2017    Published: October 26, 2017


Accumulating evidence showed that aberrant miRNAs expression was involved in initiation and progression of melanoma. However, the investigation of different miRNAs in melanoma remain attractive. In this research, we demonstrated that miR-610 expression was decreased in melanoma tissues and cell lines. The clinical data showed that the reduced miR-610 expression was obviously associated with adverse prognostic characteristics. Furthermore, our results suggested that miR-610 had a function of prognostic indicator for 5-year predicted-survival of melanoma patients. The ectopic overexpression of miR-610 suppressed cell proliferation, cell cycle progression and promoted apoptosis while miR-610 knockdown reversed the effect in vitro and in vivo. Additionally, miR-610 could modulate LRP6 by directly interacting to its 3’-UTR. In clinical samples of melanoma, miR-610 inversely correlated with LRP6. The biological function of miR-610 on melanoma cells was abrogated by alternation of LRP6 expression. In summary, our research indexed that miR-610 had a function of tumor suppressor in regulating the proliferation, cell cycle and apoptosis of melanoma via targeting LRP6. Hence, it may represent a novel potential therapeutic target and prognostic marker for melanoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22125